Mona Malik, Ph.D., B.Sc.

Dr. Mona Malik is a patent agent and senior technical advisor with more than a decade of experience as a law practitioner in intellectual property. Earlier in her career, Mona was a scientist for a dozen years raising to the faculty level at the University of Pennsylvania. Mona  provides scientific and legal expertise in litigations involving pharmaceutical products. She was involved in Hatch-Waxman litigations for Boniva, Actonel, Megace, Zometa, Reclast and Treanda to name a few. Mona’s other areas of focus include patent prosecution, due diligence assessment and freedom to operate analysis in areas such as pharmaceuticals, cellular biology and botany. She also supports clients in other science-related fields such as advising Biotechnology Companies on potential investment or growth opportunities. The scope of Mona’s work includes cancer therapy immunology/immunotherapy, biochemistry, pharmacology, virology, oncology, plant sciences and agriculture.

Mona Malik earned a PhD from the University of Cambridge after investigating complex mechanisms of chromosomal gene recombination and gene replacement.  As a faculty member and research associate at the University of Pennsylvania working in the Department of Pulmonary, Allergy and Critical Care at the School of Medicine, she investigated the biochemistry of intracellular signaling pathways in mononuclear phagocytes and uncovered a novel mechanism of monocyte infiltration in the central nervous system of HIV-infected patients. Mona’s work in the fields of immunology, anti-cancer therapy and HIV-treatment was published in leading scientific journals.

Her work as a postdoctoral research associate at St Jude Children’s Research Hospital focused on various mechanisms responsible for cell cycle regulation and the repair of DNA lesions induced by anti-cancer therapy. Mona played a critical role in research for the advancement of cancer therapies. She defined the function of the Tyrosyl-DNA Phosphodiesterase enzyme in the repair of DNA-damage induced by DNA Topoisomerase II inhibitors, an important class of anti-cancer drugs. Her work was seminal in the further development of DNA assays to possibly use mutations of the gene Tyrosyl-DNA Phosphodiesterase 1 as a potential biomarker in cancer therapy.

Mona’s undergraduate degree is in arid-zone agriculture. She specialized in plant breeding and genetics and developed improved wheat varieties. Mona also studied food technology, soil sciences, plant pathology, animal husbandry, agronomy, entomology and horticulture.

• Hahn Loeser & Parks LLP Moves Chicago Office to New Space to Allow for Continued Expansion
  September 20, 2019
• “Monocyte Migration and LFA-1-Mediated Attachment to Brain Microvascular Endothelia is Regulated by SDF-1alpha through Lyn Kinase”
  July 01, 2008

• Author

  “An Arrestin-dependent Multi-kinase Signaling Complex Mediates MIP-1β/CCL4 Signaling and Chemotaxis of Primary Human Macrophages”

  June 13, 2009
• Author

  “BCR-ABL1 Alters SDF-1α–Mediated Adhesive Responses Through the β2 Integrin LFA-1 in Leukemia Cells”

  May 15, 2008
• Author

  “Tyrosyl-DNA Phosphodiesterase (Tdp1) Participates in the Repair of Top2-Mediated DNA Damage”

  June 13, 2006
• Author

  “Roles of Nonhomologous End-Joining Pathways in Surviving Topoisomerase II–Mediated DNA Damage”

  June 01, 2006
• Author

  “DNA Repair Functions That Control Sensitivity to Topoisomerase-Targeting Drugs”

  February 02, 2004
• Author

  “Understanding the Action of Drugs Targeting TOP2: Yeast Based Systems for Unraveling Drug Mechanisms”

  January 01, 2003
• Author

  “Study of Heritability and Genetic Advances in Wheat Crosses”

  April 03, 1995